Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.
Fiche du document
18 juillet 2019
- doi: 10.1093/ajhp/zxz106
- issn: 1079-2082
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/ajhp/zxz106
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31201774
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1535-2900
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D9580C267D8B9
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
AdministrationCiter ce document
A. Bourdin et al., « Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies. », Serveur académique Lausannois, ID : 10.1093/ajhp/zxz106
Métriques
Partage / Export
Résumé
The development and dissemination of a specialty pharmacy service to optimize fingolimod therapy management are described. Fingolimod was the first oral therapy developed to counter relapsing-remitting multiple sclerosis. Pharmacovigilance measures and individualized support are strongly recommended due to associated safety concerns. The Fingolimod Patient Support Program (F-PSP) was developed and disseminated within a community pharmacy network. The F-PSP aims to ensure responsible use of fingolimod and patient empowerment by promoting medication adherence and patient safety through a person-centered and integrated care approach. It complements basic pharmacy services through 2 interventions: medication adherence support and pharmacovigilance tailored to fingolimod. The adherence intervention combines motivational interviewing with longitudinal electronic medication adherence monitoring. The pharmacovigilance component consists of informing patients of fingolimod recommendations, reminding patients of recommended medical tests, and tracking and monitoring symptoms, especially those of potential serious adverse fingolimod reactions. A secure Web platform guides the pharmacist in conducting interviews and enables collection of patient-reported outcome data. A transition care pharmacist proposes program participation to all patients initiated on fingolimod, performs enrollment, and coordinates transfers to patient-designated community pharmacies for ongoing care. The F-PSP enables support of individual patients, and also provides real-world data, helping to bridge the gap between practice and research. The F-PSP is intended to be a generic model of a specialty pharmacy service that is transferable to any other healthcare context, specialty drug or disease.